Nicholas Stroumbakis, MD
Assistant Professor of UrologyCards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileContact Info
About
Titles
Assistant Professor of Urology
Biography
Dr. Nicholas Stroumbakis is a fellowship trained Urological Oncologist who has been in practice in Fairfield County for over 20 years. He practices general urology with an emphasis in oncology. He handles all aspects of urological ailments and matters, from disease prevention to diagnostic and surgical options. He is an expert in both minimal invasive procedures and general surgeries for all urological conditions. He completed a Urological Oncology Fellowship at Memorial Sloan Kettering after graduating from Mount Sinai School of Medicine in New York City. He is the recipient of several distinctions, including Castle Connolly Top Doctor awards and Top Doctor in Connecticut.
Appointments
Urology
Assistant ProfessorPrimary
Other Departments & Organizations
- Clinical Adult Urology
- Clinical Urology
- Urology
- Yale Medicine
Education & Training
- Fellow
- Memorial Sloan Kettering (1996)
- Urology Resident
- New York Medical College (1994)
- Intern
- New York Medical College (1990)
Research
Research at a Glance
Publications Timeline
Publications
1998
Incidence and clinical significance of false-negative sextant biopsies of the prostate.
Rabbani F, Stroumbakis N, Kava B, Cookson M, Fair W. Incidence and clinical significance of false-negative sextant biopsies of the prostate. Die Urologie 1998, 37: 660. PMID: 9887497.Peer-Reviewed Original ResearchINCIDENCE AND CLINICAL SIGNIFICANCE OF FALSE-NEGATIVE SEXTANT PROSTATE BIOPSIES
RABBANI F, STROUMBAKIS N, KAVA B, COOKSON M, FAIR W. INCIDENCE AND CLINICAL SIGNIFICANCE OF FALSE-NEGATIVE SEXTANT PROSTATE BIOPSIES. Journal Of Urology 1998, 159: 1247-1250. PMID: 9507846, DOI: 10.1016/s0022-5347(01)63574-2.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsSextant prostate biopsyFalse-negative biopsiesProstate biopsyClinical significancePathological parametersRadical prostatectomyRelapse-free survival rateNeoadjuvant hormonal therapyInitial clinical stagePositive repeat biopsyHormonal therapyMost patientsPatients 27Relapse rateRepeat biopsyClinical parametersClinical stageSextant biopsyTrue incidenceTreatment modalitiesSignificant cancerProstate cancerHigh incidenceBiopsySurvival rateINCIDENCE AND CLINICAL SIGNIFICANCE OF FALSE-NEGATIVE SEXTANT PROSTATE BIOPSIES
RABBANI F, STROUMBAKIS N, KAVA B, COOKSON M, FAIR W. INCIDENCE AND CLINICAL SIGNIFICANCE OF FALSE-NEGATIVE SEXTANT PROSTATE BIOPSIES. Journal Of Urology 1998, 159: 1247-1250.. DOI: 10.1097/00005392-199804000-00047.Peer-Reviewed Original ResearchConceptsSextant prostate biopsyFalse-negative biopsiesProstate biopsyClinical significancePathological parametersRadical prostatectomyRelapse-free survival rateNeoadjuvant hormonal therapyInitial clinical stagePositive repeat biopsyHormonal therapyMost patientsPatients 27Relapse rateRepeat biopsyClinical parametersClinical stageSextant biopsyTrue incidenceTreatment modalitiesSignificant cancerProstate cancerHigh incidenceAbstract PurposeBiopsy
1997
RADICAL CYSTECTOMY IN THE OCTOGENARIAN
Stroumbakis N, Herr H, Cookson M, Fair W. RADICAL CYSTECTOMY IN THE OCTOGENARIAN. Journal Of Urology 1997, 158: 2113-2117. PMID: 9366325, DOI: 10.1016/s0022-5347(01)68171-0.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsInvasive bladder cancerBladder cancerMedian performance statusOutcome of cystectomyUse of cystectomyMedian hospital stayPatients 80 yearsMore medical problemsMedian survival timePatients 78Surgery 66Acceptable morbidityHospital stayOperative mortalityComplication ratePerformance statusSurgical complicationsMedian ageRadical cystectomySurgical reasonsUrinary diversionMedical illnessIntensive careFunctional statusQuality survivalUreteral Carcinoma in Situ at Radical Cystectomy: Does the Margin Matter?
Silver D, Stroumbakis N, Russo P, Fair W, Herr H. Ureteral Carcinoma in Situ at Radical Cystectomy: Does the Margin Matter? Journal Of Urology 1997, 158: 768-771. DOI: 10.1016/s0022-5347(01)64312-x.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsUreteral carcinomaRadical cystectomyCarcinoma recurrencePositive cytologyMargin statusBladder cancerBacillus Calmette-Guerin treatmentRenal pelvis/ureterConsecutive radical cystectomiesUpper tract carcinomaUpper tract recurrenceCancer-specific survivalMetastatic bladder cancerPositive urinary cytologyFrozen section examinationLack of morbidityBladder tumor stageExpectant managementTract recurrenceMedian followupUreteral resectionSpecific survivalNegative marginsBladder tumorsTumor stageUreteral Carcinoma in Situ at Radical Cystectomy
Silver D, Stroumbakis N, Russo P, Fair W, Herr H. Ureteral Carcinoma in Situ at Radical Cystectomy. Journal Of Urology 1997, 158: 768-771.. PMID: 9258077, DOI: 10.1097/00005392-199709000-00020.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsUreteral carcinomaRadical cystectomyCarcinoma recurrencePositive cytologyMargin statusBladder cancerBacillus Calmette-Guerin treatmentRenal pelvis/ureterConsecutive radical cystectomiesUpper tract carcinomaUpper tract recurrenceCancer-specific survivalMetastatic bladder cancerPositive urinary cytologyFrozen section examinationLack of morbidityBladder tumor stageUreteral marginsExpectant managementTract recurrenceMedian followupSpecific survivalUreteral resectionNegative marginsBladder tumorsEvaluating neoadjuvant therapy effectiveness on systemic disease: Use of a prostatic-specific membrane reverse transcription polymerase chain reaction
Su S, Heston W, Perroti M, Cookson M, Stroumbakis N, Huyrk R, Edwards E, Brander B, Coke J, Soloway S, Lewis A, Fair W. Evaluating neoadjuvant therapy effectiveness on systemic disease: Use of a prostatic-specific membrane reverse transcription polymerase chain reaction. Urology 1997, 49: 95-101. PMID: 9123743, DOI: 10.1016/s0090-4295(97)00175-1.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsProstatic specific membrane antigenAndrogen deprivation therapyNeoadjuvant androgen deprivation therapyADT groupReverse transcription-polymerase chain reactionDeprivation therapyTranscription-polymerase chain reactionControl groupProstatic cellsTumor cellsPT2 patientsPT3 patientsSystemic diseasePolymerase chain reactionEffectiveness of ADTMemorial Sloan-Kettering Cancer CenterSerum PSA valuesProstate cancer patientsChain reactionHigher positive rateProstatic epithelial cellsPT3 lesionsControl patientsExtraprostatic diseaseAdditional patientsClinical significance of repeat sextant biopsies in prostate cancer patients
Stroumbakis N, Cookson M, Reuter V, Fair W. Clinical significance of repeat sextant biopsies in prostate cancer patients. Urology 1997, 49: 113-118. PMID: 9123730, DOI: 10.1016/s0090-4295(97)00178-7.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsProstate-specific antigenOrgan-confined rateMargin-positive rateProstate cancerPSA densityRebiopsy resultsRepeat biopsySextant biopsyFinal surgical margin statusRandom systematic core biopsiesGreater prostate volumeNegative repeat biopsyAndrogen deprivation therapySurgical margin statusLower clinical stageProstate cancer patientsSignificant prostate cancerBiopsy-proven prostate cancerDeprivation therapyPositive rebiopsyConsecutive patientsInitial biopsyMargin statusProstate volumeT stageThe indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results
Fair W, Cookson M, Stroumbakis N, Cohen D, Aprikian A, Wang Y, Russo P, Soloway S, Sogani P, Sheinfeld J, Herr H, Dalgabni G, Begg C, Heston W, Reuter V. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology 1997, 49: 46-55. PMID: 9123736, DOI: 10.1016/s0090-4295(97)00169-6.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsAndrogen deprivation therapyMargin-positive rateADT groupPathologic stagingRadical prostatectomyProstatic cancerMonths of ADTControl groupNeoadjuvant androgen deprivation therapyPreoperative androgen deprivation therapyDisease-free survival ratesDisease-free rateMonths of goserelinNeoadjuvant androgen deprivationPSA failure ratesPhase II studySubset of patientsAdditional therapeutic interventionsArea of oncologyDefinitive surgeryDeprivation therapyNeoadjuvant chemotherapyPSA failureBiochemical failureControl patients
1995
Metastatic breast cancer to the bladder: A case report
Schneidau T, Stroumbakis N, Choudhury M, Eshgi M, Mallouh C. Metastatic breast cancer to the bladder: A case report. International Urology And Nephrology 1995, 27: 297-300. PMID: 7591593, DOI: 10.1007/bf02564765.Peer-Reviewed Original Research
Clinical Care
Overview
Nicholas Stroumbakis, MD, is a urologist with a special interest in cancer, from prevention of diseases to treating complicated cancer patients. Patients with cancer in the prostate, bladder, kidney, and other areas are offered up-to-date treatment options from observation to aggressive treatments with emphasis on evidence-based recommendations.
Dr. Stroumbakis also treats patients with enlarged prostate, erectile dysfunction, kidney stones, urinary tract infections, overactive bladder, incontinence, and other general urologic conditions in both men and women. Acknowledging that discussing urology problems might be awkward for some patients, Dr. Stroumbakis says he makes a point to put patients at ease.
“You don’t ever want to underestimate how serious the issue is, but I do try to make them comfortable,” he says. “I enjoy building strong relationships with my patients. Often, I see patients with recurrent issues that can’t be cured, but they can be managed well. The majority of my patients have conditions that can be treated and cared with satisfying results.”
Clinical Specialties
Fact Sheets
Prostatic Artery Embolization
Learn More on Yale MedicineUrinary Retention
Learn More on Yale MedicineSexually Transmitted Infections (STIs)
Learn More on Yale MedicineUroLift
Learn More on Yale Medicine
Board Certifications
Urology
- Certification Organization
- AB of Urology
- Original Certification Date
- 1998
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
News
Get In Touch
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.